Jennifer Pritzker Sells 250,000 Shares of Alphatec (NASDAQ:ATEC) Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) major shareholder Jennifer Pritzker sold 250,000 shares of the stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $20.62, for a total value of $5,155,000.00. Following the sale, the insider directly owned 10,895,045 shares of the company’s stock, valued at $224,655,827.90. The trade was a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Alphatec Trading Up 3.5%

NASDAQ:ATEC opened at $22.59 on Friday. Alphatec Holdings, Inc. has a 12-month low of $8.69 and a 12-month high of $22.66. The company has a current ratio of 2.88, a quick ratio of 1.77 and a debt-to-equity ratio of 23.22. The stock’s 50 day simple moving average is $17.03 and its 200-day simple moving average is $14.44. The firm has a market cap of $3.36 billion, a P/E ratio of -19.99 and a beta of 1.17.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings data on Thursday, October 30th. The medical technology company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.09. The firm had revenue of $196.50 million during the quarter, compared to analysts’ expectations of $182.78 million. The business’s quarterly revenue was up 30.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.28) earnings per share. Alphatec has set its FY 2025 guidance at EPS. Equities analysts anticipate that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Analyst Upgrades and Downgrades

ATEC has been the topic of a number of analyst reports. Wells Fargo & Company lifted their price objective on Alphatec from $14.00 to $16.00 and gave the company an “overweight” rating in a report on Thursday, October 16th. Piper Sandler restated an “overweight” rating and issued a $25.00 price target (up from $20.00) on shares of Alphatec in a research note on Friday, October 31st. HC Wainwright upped their price objective on Alphatec from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Needham & Company LLC raised their target price on Alphatec from $16.00 to $22.00 and gave the company a “buy” rating in a report on Friday, October 31st. Finally, JPMorgan Chase & Co. began coverage on shares of Alphatec in a research report on Friday, October 24th. They set an “overweight” rating and a $19.00 target price on the stock. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $22.00.

Institutional Investors Weigh In On Alphatec

Institutional investors and hedge funds have recently made changes to their positions in the business. Nuveen LLC purchased a new position in Alphatec during the 1st quarter valued at about $135,874,000. Granite Investment Partners LLC increased its stake in shares of Alphatec by 320.6% during the 2nd quarter. Granite Investment Partners LLC now owns 1,720,944 shares of the medical technology company’s stock worth $19,102,000 after purchasing an additional 1,311,748 shares in the last quarter. MetLife Investment Management LLC increased its stake in shares of Alphatec by 1,818.5% during the 1st quarter. MetLife Investment Management LLC now owns 1,213,943 shares of the medical technology company’s stock worth $12,309,000 after purchasing an additional 1,150,669 shares in the last quarter. Driehaus Capital Management LLC acquired a new position in shares of Alphatec during the 1st quarter worth approximately $10,398,000. Finally, Motley Fool Wealth Management LLC purchased a new stake in Alphatec in the 1st quarter valued at approximately $9,070,000. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.